Managing patients with metastatic colorectal cancer on bevacizumab

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Bevacizumab (Avastin) is a monoclonal antibody targeting vascular endothelial growth factor (VEGF).
• VEGF is crucial for tumor angiogenesis, the formation of new blood vessels that feed tumors.
• Inhibiting VEGF with bevacizumab can impede tumor growth and survival.

Purpose of the Study:

• To evaluate the efficacy of bevacizumab in combination with chemotherapy for metastatic colorectal cancer (CRC).
• To describe the side-effect profile of bevacizumab and its management.
• To highlight the role of oncology nurses in optimizing bevacizumab therapy.

Main Methods:

• Clinical trials assessing bevacizumab plus chemotherapy versus chemotherapy alone in first-line metastatic CRC.
• Analysis of bevacizumab's specific adverse events, including hypertension, proteinuria, thromboembolic events, wound healing complications, bleeding, and gastrointestinal perforation.
• Review of nursing interventions for patient education and side-effect management.

Main Results:

• First-line bevacizumab combined with chemotherapy improves outcomes in metastatic CRC compared to chemotherapy alone.
• Bevacizumab's side-effect profile is distinct from conventional chemotherapy and does not significantly worsen chemotherapy-induced toxicities.
• Key bevacizumab-related side effects require vigilant monitoring and management.

Conclusions:

• Bevacizumab is an effective addition to chemotherapy for metastatic CRC, enhancing patient outcomes.
• Understanding and managing bevacizumab's specific side effects is crucial for patient safety and treatment success.
• Oncology nurses are essential for educating patients and managing adverse events, thereby maximizing the benefits of bevacizumab therapy.